FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1680472002> ?p ?o ?g. }

• W1680472002 endingPage "362" @default.
• W1680472002 startingPage "355" @default.
• W1680472002 abstract "The purpose of this study was to investigate the tolerability, pharmacokinetics, and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, during chronic infusions in healthy male subjects.Tezosentan was infused at a rate of 100 mg h(-1) for 6 h (study A, six subjects) and at a rate of 5 mg h(-1) for 72 h (study B, eight subjects). Both studies had a randomized, placebo-controlled, double-blind design. Tolerability and safety were monitored by the recording of vital signs, ECG, adverse events and clinical laboratory parameters. Blood samples were collected frequently for pharmacokinetic determinations and measurement of plasma endothelin-1 concentrations.In both studies tezosentan was well tolerated with headache the most frequently reported adverse event (incidence of 75-100% for tezosentan and 50% for placebo). Plasma concentrations of tezosentan rapidly approached steady state (3000 and 125 ng ml(-1) in study A and B, respectively) and did not change upon prolonged infusion. A two-compartment model could describe its pharmacokinetic profile. The half-lives of the two disposition phases were approximately 0.10 and 3.2 h. Endothelin-1 concentrations increased rapidly 11- and 2-fold compared with pre-dose values in study A and B, respectively, during infusion of tezosentan and did not change during the 72 h infusion.On the basis of these results, dose finding studies with tezosentan in acute heart failure can be initiated in the dose range 5-100 mg h(-1)." @default.
• W1680472002 created "2016-06-24" @default.
• W1680472002 creator A5020829373 @default.
• W1680472002 creator A5026460285 @default.
• W1680472002 creator A5058093690 @default.
• W1680472002 date "2002-04-01" @default.
• W1680472002 modified "2023-10-18" @default.
• W1680472002 title "Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects" @default.
• W1680472002 cites W1569769209 @default.
• W1680472002 cites W1977343715 @default.
• W1680472002 cites W1979604318 @default.
• W1680472002 cites W1983631460 @default.
• W1680472002 cites W1990427434 @default.
• W1680472002 cites W1992583442 @default.
• W1680472002 cites W1993972994 @default.
• W1680472002 cites W2000892838 @default.
• W1680472002 cites W2004701138 @default.
• W1680472002 cites W2020738602 @default.
• W1680472002 cites W2025252445 @default.
• W1680472002 cites W2044327576 @default.
• W1680472002 cites W2060989736 @default.
• W1680472002 cites W2104825830 @default.
• W1680472002 cites W2110857859 @default.
• W1680472002 cites W2122348312 @default.
• W1680472002 cites W2162804111 @default.
• W1680472002 cites W2181880038 @default.
• W1680472002 cites W2186702536 @default.
• W1680472002 cites W2315872753 @default.
• W1680472002 cites W2336346210 @default.
• W1680472002 cites W2502670554 @default.
• W1680472002 cites W2051247875 @default.
• W1680472002 doi "https://doi.org/10.1046/j.1365-2125.2002.01158.x" @default.
• W1680472002 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1874269" @default.
• W1680472002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11966665" @default.
• W1680472002 hasPublicationYear "2002" @default.
• W1680472002 type Work @default.
• W1680472002 sameAs 1680472002 @default.
• W1680472002 citedByCount "32" @default.
• W1680472002 countsByYear W16804720022014 @default.
• W1680472002 countsByYear W16804720022017 @default.
• W1680472002 countsByYear W16804720022018 @default.
• W1680472002 countsByYear W16804720022019 @default.
• W1680472002 countsByYear W16804720022020 @default.
• W1680472002 countsByYear W16804720022022 @default.
• W1680472002 countsByYear W16804720022023 @default.
• W1680472002 crossrefType "journal-article" @default.
• W1680472002 hasAuthorship W1680472002A5020829373 @default.
• W1680472002 hasAuthorship W1680472002A5026460285 @default.
• W1680472002 hasAuthorship W1680472002A5058093690 @default.
• W1680472002 hasBestOaLocation W16804720022 @default.
• W1680472002 hasConcept C111113717 @default.
• W1680472002 hasConcept C112705442 @default.
• W1680472002 hasConcept C126322002 @default.
• W1680472002 hasConcept C142724271 @default.
• W1680472002 hasConcept C144980905 @default.
• W1680472002 hasConcept C170493617 @default.
• W1680472002 hasConcept C197934379 @default.
• W1680472002 hasConcept C204787440 @default.
• W1680472002 hasConcept C27081682 @default.
• W1680472002 hasConcept C2776345702 @default.
• W1680472002 hasConcept C2778375690 @default.
• W1680472002 hasConcept C42219234 @default.
• W1680472002 hasConcept C71924100 @default.
• W1680472002 hasConcept C98274493 @default.
• W1680472002 hasConceptScore W1680472002C111113717 @default.
• W1680472002 hasConceptScore W1680472002C112705442 @default.
• W1680472002 hasConceptScore W1680472002C126322002 @default.
• W1680472002 hasConceptScore W1680472002C142724271 @default.
• W1680472002 hasConceptScore W1680472002C144980905 @default.
• W1680472002 hasConceptScore W1680472002C170493617 @default.
• W1680472002 hasConceptScore W1680472002C197934379 @default.
• W1680472002 hasConceptScore W1680472002C204787440 @default.
• W1680472002 hasConceptScore W1680472002C27081682 @default.
• W1680472002 hasConceptScore W1680472002C2776345702 @default.
• W1680472002 hasConceptScore W1680472002C2778375690 @default.
• W1680472002 hasConceptScore W1680472002C42219234 @default.
• W1680472002 hasConceptScore W1680472002C71924100 @default.
• W1680472002 hasConceptScore W1680472002C98274493 @default.
• W1680472002 hasIssue "4" @default.
• W1680472002 hasLocation W16804720021 @default.
• W1680472002 hasLocation W16804720022 @default.
• W1680472002 hasLocation W16804720023 @default.
• W1680472002 hasLocation W16804720024 @default.
• W1680472002 hasOpenAccess W1680472002 @default.
• W1680472002 hasPrimaryLocation W16804720021 @default.
• W1680472002 hasRelatedWork W1979626596 @default.
• W1680472002 hasRelatedWork W1986060795 @default.
• W1680472002 hasRelatedWork W2040354764 @default.
• W1680472002 hasRelatedWork W2116152202 @default.
• W1680472002 hasRelatedWork W2254638634 @default.
• W1680472002 hasRelatedWork W2369345461 @default.
• W1680472002 hasRelatedWork W2369362743 @default.
• W1680472002 hasRelatedWork W2381977691 @default.
• W1680472002 hasRelatedWork W2418287413 @default.
• W1680472002 hasRelatedWork W2898845055 @default.
• W1680472002 hasVolume "53" @default.
• W1680472002 isParatext "false" @default.
• W1680472002 isRetracted "false" @default.

• next